摘要:
The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.
摘要:
Imprimante tridimensionnelle (1, 2, 3) pour une fabrication d'une préparation alimentaire (52) à partir d'au moins un aliment (5), comprenant au moins un réservoir (6) contenant l'au moins un aliment (5), et au moins une buse d'extrusion (7) configurée pour déposer un cordon (51) dudit aliment (5) sur une surface d'impression (82) , caractérisée en ce que l'au moins une buse d'extrusion (7) comporte un élément de cuisson (71) configuré pour réaliser par chauffage tout ou partie d'une cuisson du cordon (51) avant un contact avec la surface d'impression (82).
摘要:
The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.